BiotechTube
Uniquity Bio

Uniquity Bio

New York, United States· Est.
uniquity.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $100M

Overview

Uniquity Bio is a private, clinical-stage biotech founded in 2022 and headquartered in New York, USA. The company is building a pipeline in immunology and inflammation, anchored by its lead in-licensed asset, solrikitug (anti-TSLP mAb), which is currently in Phase 2 trials for COPD, asthma, and eosinophilic esophagitis (EoE). Backed by Blackstone Life Sciences, Uniquity combines experienced leadership with committed capital to strategically identify and advance under-explored therapeutic opportunities for patients with limited treatment options.

ImmunologyInflammationRespiratoryGastrointestinal

Technology Platform

Strategic development engine focused on in-licensing and optimizing clinical-stage biologics, with a core expertise in monoclonal and bispecific antibodies targeting immune pathways like TSLP.

Funding History

1
Total raised:$100M
Series A$100M

Opportunities

Large and growing markets for severe respiratory and GI diseases with significant unmet need provide a substantial addressable opportunity.
Demonstrating best-in-class efficacy for its TSLP inhibitor could allow Uniquity to capture market share in competitive spaces and lead in niche indications.
The bispecific pipeline offers a path to expand its franchise and address broader patient populations.

Risk Factors

High clinical development risk as the company's value is concentrated on the success of solrikitug in ongoing Phase 2 trials.
It faces intense competition from established TSLP inhibitors and other biologic classes in immunology.
The company's financial and strategic dependence on its single major investor, Blackstone, introduces a potential vulnerability.

Competitive Landscape

Uniquity competes in the crowded immunology space, directly against AstraZeneca's approved TSLP inhibitor, tezepelumab, and other cytokine-targeting biologics for asthma, COPD, and EoE. Its strategy hinges on dose optimization to achieve superior efficacy. It also competes for partnership opportunities and talent with other well-funded, agile biotechs in the I&I sector.

More companies in Biologics / Biosimilars →More companies in United States →